Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Novo Nordisk typically reports earnings before the U.S. market opens, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-06 | +$0.89 (+1.98%) | $2.02 (4.50%) | +$0.04 (+0.09%) | $1.33 (2.91%) |
| 2026-02-04 | -$3.11 (-6.18%) | $2.63 (5.23%) | -$3.85 (-8.16%) | $2.43 (5.15%) |
| 2025-11-05 | +$0.21 (+0.44%) | $2.84 (5.89%) | -$1.95 (-4.02%) | $3.28 (6.76%) |
| 2025-08-06 | -$1.84 (-3.90%) | $1.44 (3.05%) | +$3.38 (+7.45%) | $1.18 (2.60%) |
| 2025-05-07 | +$1.26 (+1.90%) | $2.85 (4.30%) | -$2.70 (-4.00%) | $1.56 (2.31%) |
| 2025-02-05 | +$3.11 (+3.76%) | $2.33 (2.82%) | +$1.44 (+1.68%) | $2.28 (2.66%) |
| 2024-11-06 | -$4.77 (-4.33%) | $3.72 (3.38%) | +$2.27 (+2.15%) | $2.15 (2.04%) |
| 2024-08-07 | -$10.89 (-8.37%) | $4.82 (3.70%) | +$8.94 (+7.50%) | $5.13 (4.30%) |
| Avg Abs Move | 3.86% | 4.11% | 4.38% | 3.59% |
Historical price action around Novo Nordisk earnings reveals significant volatility, with an average absolute Day 0 move of 3.86% and Day +1 move of 4.38%. The stock has shown no consistent directional bias, with reactions ranging from an 8.37% decline (August 2024) to a 3.76% gain (February 2025) on announcement day. Notably, Day +1 moves have frequently reversed the initial reaction—after the 8.37% drop in August 2024, the stock rebounded 7.50% the following session, while the 1.90% gain in May 2025 was followed by a 4.00% decline.
The most recent earnings release in May 2026 produced a relatively muted 1.98% Day 0 gain followed by a minimal 0.09% Day +1 move, suggesting investors may have already priced in the strong results. The February 2026 report triggered a sharp 6.18% Day 0 decline despite a positive earnings surprise, indicating concerns about forward guidance or competitive dynamics overshadowed the beat. This pattern of volatile, sometimes counterintuitive reactions underscores the importance of guidance and management commentary beyond the headline numbers.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/07/26 (DTE 3) |
| Expected Move | $1.47 (3.32%) |
| Expected Range | $42.81 to $45.75 |
| Implied Volatility | 53.43% |
The options market is pricing an expected move of 3.32% for this earnings release, which sits below the stock's average historical Day 0 move of 3.86% and well below the average Day +1 move of 4.38%. This suggests options traders may be underestimating potential volatility, particularly given the stock's history of sharp reversals in the session following earnings announcements.
Part 3: What Analysts Are Saying
Analyst sentiment toward Novo Nordisk reflects cautious positioning, with the consensus rating at 3.00 (Hold) and an average price target of $47.28—implying 6.8% upside from the current price of $44.28. The analyst community is divided, with 2 Strong Buy ratings and 19 Hold ratings, but also 2 Strong Sell ratings, indicating meaningful disagreement about the stock's prospects.
Sentiment has deteriorated over the past month, with the average recommendation slipping from 3.09 to 3.00 and one analyst downgrading from Hold to Strong Sell. This shift reflects growing concerns about competitive pressures and valuation following the stock's substantial run-up in prior years. The price target range is wide, spanning from a low of $40.00 to a high of $55.23, with the high-end target suggesting 24.7% upside for bulls while the low-end implies 9.7% downside risk.
The deteriorating sentiment trend aligns with the sharp decline in expected earnings growth, as analysts appear to be recalibrating expectations for a more competitive and margin-pressured environment. The concentration of Hold ratings suggests most analysts are adopting a wait-and-see approach, looking for evidence that Novo can sustain its growth trajectory before recommending accumulation at current levels.
Part 4: Technical Picture
Novo Nordisk enters earnings with a weakening technical picture, as the Barchart Technical Opinion has deteriorated sharply from 72% Buy one week ago to just 8% Buy currently, while maintaining a Buy signal one month ago at 40%. This rapid decline in technical strength suggests momentum has stalled heading into the report.
Timeframe Analysis:
- Short-term (50% Buy): Moderate buy signal indicates near-term momentum remains marginally positive but has weakened considerably
- Medium-term (50% Buy): Neutral-to-positive reading suggests the intermediate trend is balanced between bullish and bearish forces
- Long-term (50% Sell): Moderate sell signal reflects underlying weakness in the longer-term trend structure
Trend Characteristics: The signal strength is at Minimum levels with the Weakest directional conviction, indicating the stock lacks a clear trend bias and may be vulnerable to sharp moves in either direction on earnings.
The stock is trading at $44.28, positioned below its 5-day ($48.33), 10-day ($48.74), 20-day ($49.22), 50-day ($46.87), and 200-day ($46.84) moving averages, though it remains above the 100-day average at $43.65. This configuration shows the stock in a short-term downtrend, having broken below key support levels.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $48.33 | 50-Day MA | $46.87 |
| 10-Day MA | $48.74 | 100-Day MA | $43.65 |
| 20-Day MA | $49.22 | 200-Day MA | $46.84 |
The technical setup heading into earnings is cautionary, with NVO trading below most major moving averages and showing deteriorating momentum across all timeframes. The stock's failure to hold above the 50-day and 200-day moving averages suggests institutional support has weakened. The $46.84 level (200-day MA) represents key overhead resistance, while the $43.65 level (100-day MA) provides nearby support. Given the weak technical positioning, the stock may need a significant positive surprise to generate sustained upside momentum, while any disappointment could accelerate the recent downtrend toward the $40.00 analyst low target.